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INTRODUCTION 
METODOLOGY 
 
LI-FRAUMENI SYNDROME 
COWDEN SYNDROME 
PALB2 HEREDITARY BREAST CANCER 
REFERENCES 
 Most common cancer in women (1,7 million cases each year) 
 Risk factors: genes, advanced age, smoke, alcohol, hormones, diet… 
 Hereditary breast cancer? Multiple family cases, young ages (<40), bilateral, male BC 
 BRCA are the most common BC predisposition genes (1:400-1:800 carrier) 
 5% caused by HIGH PENETRANCE GENES with AD inherited pattern and less known than BRCA 
 Risk families diagnosis and adequate cancer surveillance can reduce mortality  
I have done a review of actual journal articles published in 
PubMed. I also have consulted several web pages like OMIM, 
GeneReviews, Genetic Home Reference, GeneCards, 
UniProt,…and I have read Genetic Counseling books 
OBJECTIVES  
 The aim of this review is search important high-penetrant genes that predispose to BC and are less-known than 
BRCA in order to do BC prevention and early diagnosis in 
high risk families  
SURVEILLANCE 
This family have Chompret criteria because the proband 
have BC <45 years and 1st degree of soft tissue sarcoma a 
part of pediatric brain tumors and all other cancers described 
SURVEILLANCE 
SURVEILLANCE 
TP53 
PTEN 
PALB2 
This family met two major criteria (breast and endometrial 
cancer) 
Testing criteria: three BC cases, one in each 
generation 
Breast 
   35%-47,5% 
    8,3 fold 
increased risk 
 
Pancreas 
10-32 fold 
increased risk 
MALIGNANCIES  
Other: Ovary 2,3 fold increase risk 
Increased risk of lung and prostate 
CASE REPORT 
CASE REPORT 
CASE REPORT 
MALIGNANCIES  
MALIGNANCIES  
Other: Colon (9%), kidney (34%) and melanoma (6%). 
35% of patients have digestive benign polyps  
Endometrium 
28% 
*36-46 
Breast 
   50%-85% 
50% at age 50 
*36-46 
    increased                        
risk 
 
Thyroid 
10%-35% 
*10-15 or 36-46 
usually follicular, 
rarely papillary, 
but never 
medullary 
75% benign 
thyroid 
pathology  
 
Sarcoma 
17,8% *0-10 
Osteosarc 
13,5% *11-20 
 
Breast 
     age 60: 90% 
    *20s-30s 
Bilateral: 10-20 fold 
increased 
     increased risk 
 
Brain  
14% 
*0-10 or >20 
 
Adrenocortical 
6,5% 
*0-10 
 
Leukemia, lymphoma, lung, colorectal, 
gastric, melanoma and ovarian 
*Median age at onset 
FUNCTION: DNA damage response 
and tumor suppressor gene 
FREQUENCY: 1:5,000-1:20,000 
De novo: 7%-20% 
MUTATIONS: 
 95% missense mutations exons 4-9 
(early onset and high risk) 
 1% large rearrangements 
 CANCER RISK 
50% by age 30 and 90% by age 50 
45% of patients have >1 type of cancer 
Life time risk:  
 Female: 100% (median age at onset 29) 
Male: 73% (median age at onset 40) 
Cause 0,1% of all BC 
CLINICAL DIAGNOSIS 
 Early onset and multiple tumors in a 
patient 
Multiple affected family members 
 1 or >1 family member with a sarcoma, 
BC, brain c, or adrenocortical c.  
TESTING CRITERIA: Chompret criteria  
FUNCTION: tumor suppressor gene with  
phosphatase activity  
FREQUENCY: 1:200,000 
MUTATIONS: 
 80% in the codificant region  
 10% promoter mutations (associated with BC) 
 40% in phosphate core motif 
 76%: truncated, lack or dysfunctional protein 
 
Life time risk of 85% by age 70 
 Female: 87% by age 60 
Male: 56% by age 60 
BC typically ductal adenocarcinoma 
surrounded by hyalinised collagen 
67-75% benign breast disease  
Cause 0.02% of all BC 
   CLINICAL DIAGNOSIS 
 99% present skin manifestations at 
age 30 (hamartomatous lesions, 
trichilemmomas, acral keratosis and 
papillomatous papules) 
 Other: gastrointestinal hamartomas, 
macrocephalia, developmental 
delay, autism, pigmented macules 
on the penis  
FUNCTION: DNA damage response (partner 
/localizer of BRCA2) and tumor suppressor gene  
FREQUENCY: 1:1,000 
MUTATIONS: 
 10 known mutations associated with BC  
 In carriers, BRCA protein levels are reduced  
 Biallelic mutations cause Fanconi anemia  
CANCER RISK 
CLINICAL DIAGNOSIS: 
Several individuals with BC and 
pancreatic cancer 
TESTING CRITERIA: 
 3 or >3 family members with BC  
 Test is done when a mutation in 
BRCA is not found  
Location: 17p13.1 
Location: 10q23.3 
Location: 16p12.2 
CONCLUSIONS 
Genetic architecture of cancer risk 
Extracted from Genereviews 
RISKS  
 
BENEFITS  
 
*Median age at onset 
1  2  3               4                           5           6 7  8   9   10   11   12    13 
Oligomerization and DNA 
damage localization [1-160] 
BRCA1 interaction [1-319] 
RAD51 interaction [1-200] 
KEAP1 interaction [88-94] 
MRG15 interaction [611-764] 
BRCA2 and RAD51 
interaction [853-1186] 
 Truncating mutations  are more 
associated with BC 
 30% are triple-negative  
 Different risk depending of the 
family history 
 Cause 2.4% of all BC (0.4-3.9%) 
and 3-4% of all families with 
pancreatic cancer. 
CANCER RISK 
Clinical exam, MRI and 
echography: 20-25 years 
Abdominal ultrasound 
and whole-body MRI 
(monitor sarcomas) 
Physical examination  
and blood test 
Colonoscopy: 25-30 y 
Brain MRI 
Clinical exam, MRI, 
Mammogram: 25-30 y 
Blind endometrial 
biopsy and 
echography: 30-35 y 
Thyroid clinical exam 
and ultrasound: 18 y 
Physical exam: skin, 
mucous membranes: 18 y 
Endoscopy and 
colonoscopy: 30-35 y 
Clinical exam, MRI, 
mammogram, 
echography: 25-30 y 
Transvaginal 
ultrasound and serum 
[CA-125] : 35 y 
(ovarian surveillance) 
Digital rectal 
examination: 40 y  
(prostate surveillance) 
Ultrasound and MRI 
(if pancreatic family 
history is positive) 
*Median age at onset 
 Specific surveillance for carriers: early 
tumor detection 
 Preventive surgery: reduce risk 
 Prenatal/preimplantational diagnosis 
 Non carriers have general population 
risk even if the family history is positive 
so they avoid unnecessary screening 
 Psychological effects (feeling anxious, 
depressed…) 
 Variants of uncertain significance can 
lead a difficult genetic counseling 
 Violation of confidentiality can affect 
employment, health insurances… 
 BRCA only cause 25-30% of hereditary BC, there are other important predisposition genes 
  High-penetrance genes are important to be diagnosed to follow 
adequate surveillance (early detection), optional prophylactic 
surgeries, targeted therapies… 
 Is important to inform oncology professionals to identify at-risk families 
Gene panels to study several genes at the same time 
 Future studies: BC caused for an accumulation of frequent low-
penetrance mutations Genereviews; National Cancer institude; Economopoulou P., “Beyond BRCA: New Hereditary Breast Cancer Susceptibility Genes” 
Cancer treat rev 1. 1-8 (2015); Antoniou AC, “Breast-Cancer Risk in Families with Mutations in PALB2.” NEJM 6. 497–506 (2014) 
